A tiny, pre-revenue ICU anticoagulation bet where one Phase 3 readout can flip Talphera from “going concern” to strategic buyout target.
Overview
Talphera (TLPH), formerly AcelRx, has executed a full strategic pivot from sublingual opioid products (e.g., DSUVIA—now divested) to a single primary value driver: **Niyad**, a lyophilized nafamostat mesylate formulation being developed as a **regional anticoagulant for CRRT** under an **IDE/PMA** pathway. The company is effectively **pre-revenue**, recording only **~$28k** in non-cash legacy revenue in FY2025, and is funding operations primarily through capital raises and strategic support. Clinically, Niyad is positioned as an alternative to **heparin** (bleeding/HIT risk) and **citrate** (complex monitoring, contraindications), leveraging nafamostat’s rapid breakdown to limit systemic anticoagulation. Strategically, a major minority investment from **CorMedix** includes a **right of first negotiation**, shaping the likely endgame toward acquisition. The key near-term milestone is the **Phase 3 NEPHRO CRRT** registrational study (50% enrolled in early 2026), with a planned PMA submission and potential 2026 launch—making the story fundamentally **event-driven**.